Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olav Dalgard

Showing results (101-110 of 107) with videos related to

Pageof 11
Sort By:
You have reached the last page of results.This site can display upto 107 results.
Ebiomedicine|December 28, 2024
Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trialHans-Kittil Viermyr, Kristian Tonby, Erica Ponzi, et al.
Critical Care (London, England)|January 10, 2023
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialMarius Trøseid, José R Arribas, Lambert Assoumou, et al.
The Journal of Infection|February 17, 2024
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialMaya Hites, Clément R Massonnaud, Eva Larranaga Lapique, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 22, 2025
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trialClément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, et al.
Nature Communications|May 15, 2021
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Communications|April 16, 2021
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Communications|February 5, 2024
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Pageof 11

Showing results (101-110 of 107) with videos related to

Sort By:
Pageof 11
You have reached the last page of results.This site can display upto 107 results.
Ebiomedicine|December 28, 2024
Safety of baricitinib in vaccinated patients with severe and critical COVID-19 sub study of the randomised Bari-SolidAct trialHans-Kittil Viermyr, Kristian Tonby, Erica Ponzi, et al.
Critical Care (London, England)|January 10, 2023
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trialMarius Trøseid, José R Arribas, Lambert Assoumou, et al.
The Journal of Infection|February 17, 2024
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialMaya Hites, Clément R Massonnaud, Eva Larranaga Lapique, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|December 22, 2025
Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in hospitalized COVID-19 patients: long-term results from the DisCoVeRy trialClément R Massonnaud, Nathan Peiffer-Smadja, Pascal Poignard, et al.
Nature Communications|May 15, 2021
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Communications|April 16, 2021
Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Nature Communications|February 5, 2024
Author Correction: Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trialsCathrine Axfors, Andreas M Schmitt, Perrine Janiaud, et al.
Pageof 11